Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | CASP2 | P42575 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | TOP2A | P11388 | 1/20 | 0.31 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2064741 | 0.75 | CRBN (0.42) | CRBNHTTKMT2ACASP3CASP2 | |
| SCHEMBL3231672 | 0.73 | CRBN (0.41) | CRBNHTTKMT2ACASP3CASP2 | |
| SCHEMBL6063987 | 0.73 | CRBN (0.46) | CRBNHTTKMT2ACASP3CASP2 | |
| SCHEMBL3346307 | 0.72 | KMT2A (0.54) | CRBNHTTKMT2AMEN1ALDH1A1 | |
| SCHEMBL2185405 | 0.69 | NAMPT (0.50) | LMNASMN1; SMN2 | |
| SCHEMBL2185069 | 0.69 | NAMPT (0.50) | LMNASMN1; SMN2 | |
| SCHEMBL2186377 | 0.69 | NAMPT (0.50) | LMNASMN1; SMN2 | |
| SCHEMBL10885681 | 0.68 | CASP3 (0.42) | CRBNHTTKMT2ACASP3CASP2 | |
| SCHEMBL11004284 | 0.68 | CRBN (0.37) | CRBNHTTKMT2ACASP3CASP2 | |
| SCHEMBL11735286 | 0.68 | CRBN (0.37) | CRBNHTTKMT2ACASP3CASP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110143925-B | Hydantoin hydroxamic acid histone deacetylase 6 subtype selective inhibitor, and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | claimed |
| CN-110143925-B | Hydantoin hydroxamic acid histone deacetylase 6 subtype selective inhibitor, and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | disclosed |
| CN-110143925-B | Hydantoin hydroxamic acid histone deacetylase 6 subtype selective inhibitor, and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | disclosed |
| CN-110143925-B | Hydantoin hydroxamic acid histone deacetylase 6 subtype selective inhibitor, and preparation method and application thereof | 山东大学 | 2022-10-25 | — | — | CN | disclosed |
| US-8338471-B2 | (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2012-12-25 | — | — | US | disclosed |
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2012-01-19 | — | — | US | disclosed |
| US-8022092-B2 | (2,5-dioxoimidazolidin-1-yl)-N-hydroxy-acetamides as metalloproteinase inhibitors | MEDIVIR AB (SE) | 2011-09-20 | — | — | US | disclosed |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2009-08-27 | — | — | US | disclosed |
| EP-1966153-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | Medivir AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068474-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MEDIVIR AB (SE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015994-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | CRBN 4243/4885HTT 2009/4885KMT2A 1287/4885 |
| US-20090215846-A1 | (2,5-DIOXOIMIDAZOLIDIN-I-YL)-N-HYDROXY-ACETAMIDES AS METALLOPROTEINASE INHIBITORS | MMP12, MMP13, MMP14 | CRBN 4243/4885HTT 2009/4885KMT2A 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.